Better Medicines, Created Rapidly through De Novo Protein Design
Time: 9:30 am
day: Conference Day One
Details:
- Integrating artificial intelligence, synthetic biology, and robotics to expedite the discovery and optimization of protein binders, generating a diverse array of modular miniprotein domains characterized by optimal drug-like properties and developability profiles
- Showcasing the distinct attributes of miniproteins by pioneering first-in-class NK cell engagers for oncology, along with leading therapeutics targeting TNFR1 for inflammation and GLP1R for metabolic disease
- Utilizing advanced technologies to create a vast toolbox of miniprotein domains, demonstrating their potential in addressing various medical challenges and advancing therapeutic innovation
